Results 151 to 160 of about 8,945 (197)
Drug Safety, 2012 Flecainide is a class Ic antiarrhythmic agent that has an important role as part of rhythm control strategies in patients with atrial fibrillation (AF). Early clinical data on the use of flecainide showed an increase in arrhythmias and mortality compared with placebo in patients with a previous myocardial infarction and asymptomatic or mildly ...
Tamargo, Juan +2 more
openaire +3 more sources
Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives [PDF]
Journal of Clinical Medicine, 2021 Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF).
Carlo Lavalle +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Journal of Cardiovascular Electrophysiology, 1994
Flecainide. Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic
R H, Falk, R I, Fogel
openaire +2 more sources
Flecainide. Flecainide is a Class IC antiarrhythmic agent whose primary electrophysiologic effect is a slowing of conduction in a wide range of cardiac tissues. It is well absorbed and effective in suppressing isolated premature ventricular contractions (PVCs) or nonsustained ventricular arrhythmia but has only a modest efficacy when electrophysiologic
R H, Falk, R I, Fogel
openaire +2 more sources
Journal of Analytical Toxicology, 1990
A fatal case attributed to flecainide intoxication is presented. Quantitation was by capillary gas chromatography with nitrogen-phosphorus detection. The flecainide concentration in the blood was 13 mg/L as compared to a therapeutic range in serum of 0.2-1.0 mg/L.
B, Levine, D, Chute, Y H, Caplan
openaire +2 more sources
A fatal case attributed to flecainide intoxication is presented. Quantitation was by capillary gas chromatography with nitrogen-phosphorus detection. The flecainide concentration in the blood was 13 mg/L as compared to a therapeutic range in serum of 0.2-1.0 mg/L.
B, Levine, D, Chute, Y H, Caplan
openaire +2 more sources
European Heart Journal, 1987
Flecainide and encainide (class IC) are presently under clinical evaluation in Italy. They prolong the duration of the QRS but not the period of ventricular repolarisation: the prolongation of QT is due solely to the prolongation of the Q-J.
F, Furlanello +5 more
openaire +2 more sources
Flecainide and encainide (class IC) are presently under clinical evaluation in Italy. They prolong the duration of the QRS but not the period of ventricular repolarisation: the prolongation of QT is due solely to the prolongation of the Q-J.
F, Furlanello +5 more
openaire +2 more sources
Flecainide How and When: A Practical Guide in Supraventricular Arrhythmias [PDF]
Journal of Clinical Medicine, 2021 Transcatheter ablation was increasingly and successfully used to treat symptomatic drug refractory patients affected by supraventricular arrhythmias. Antiarrhythmic drug treatment still plays a major role in patient management, alone or combined with non-
Carlo Lavalle, Michele Magnocavallo
exaly +2 more sources
The American Journal of Cardiology, 1984
After oral administration in healthy human subjects, flecainide absorption is prompt (average peak level at 3 to 4 hours) and nearly complete (at least 90%); flecainide does not appear to undergo consequential presystemic biotransformation. Oral absorption in patients with cardiac arrhythmias, renal disease and congestive heart failure (CHF) is also ...
G J, Conard, R E, Ober
openaire +2 more sources
After oral administration in healthy human subjects, flecainide absorption is prompt (average peak level at 3 to 4 hours) and nearly complete (at least 90%); flecainide does not appear to undergo consequential presystemic biotransformation. Oral absorption in patients with cardiac arrhythmias, renal disease and congestive heart failure (CHF) is also ...
G J, Conard, R E, Ober
openaire +2 more sources
Flecainide Test in Brugada Syndrome: A Reproducible but Risky Tool [PDF]
PACE - Pacing and Clinical Electrophysiology, 2003 The flecainide test is widely used in Brugada syndrome. However, its reproducibility and safety remain ill-defined. This study included 22 patients (18 men, mean age 34 years). Mutations in the SCN5A gene were found in eight patients.
Paola Galimberti, Carlo Ceriotti
exaly +1 more source